Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
electroCore, Inc. stock logo
ECOR
electroCore
$4.80
+1.2%
$6.04
$4.16
$19.49
$36.35M0.36125,676 shs40,582 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.28
-4.4%
$1.82
$1.30
$7.00
$120.95M1.621.32 million shs1.22 million shs
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$14.50
-0.9%
$14.56
$12.76
$27.28
$138.73M1.11128,377 shs93,041 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$12.32
-1.2%
$12.74
$3.80
$17.31
$147.04M0.49124,122 shs11,722 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
electroCore, Inc. stock logo
ECOR
electroCore
0.00%-3.07%-9.54%-9.20%-22.30%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-14.70%+27.96%+19.00%-65.05%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
0.00%-2.34%-2.27%+6.32%-28.74%
LENSAR, Inc. stock logo
LNSR
LENSAR
0.00%+2.47%-1.42%+2.05%+146.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
electroCore, Inc. stock logo
ECOR
electroCore
$4.80
+1.2%
$6.04
$4.16
$19.49
$36.35M0.36125,676 shs40,582 shs
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$2.28
-4.4%
$1.82
$1.30
$7.00
$120.95M1.621.32 million shs1.22 million shs
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$14.50
-0.9%
$14.56
$12.76
$27.28
$138.73M1.11128,377 shs93,041 shs
LENSAR, Inc. stock logo
LNSR
LENSAR
$12.32
-1.2%
$12.74
$3.80
$17.31
$147.04M0.49124,122 shs11,722 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
electroCore, Inc. stock logo
ECOR
electroCore
0.00%-3.07%-9.54%-9.20%-22.30%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
0.00%-14.70%+27.96%+19.00%-65.05%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
0.00%-2.34%-2.27%+6.32%-28.74%
LENSAR, Inc. stock logo
LNSR
LENSAR
0.00%+2.47%-1.42%+2.05%+146.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
electroCore, Inc. stock logo
ECOR
electroCore
3.00
Buy$25.50431.80% Upside
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.50
Moderate Buy$8.80286.81% Upside
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
2.75
Moderate Buy$25.0072.47% Upside
LENSAR, Inc. stock logo
LNSR
LENSAR
2.00
Hold$15.0021.80% Upside

Current Analyst Ratings Breakdown

Latest ECOR, INO, LNSR, and LAKE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
DA Davidson
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$23.00 ➝ $20.00
9/3/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/14/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$3.00
8/14/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
7/9/2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOverweight$5.00
(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
electroCore, Inc. stock logo
ECOR
electroCore
$25.18M1.44N/AN/A$1.13 per share4.24
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
$182.34K663.06N/AN/A$1.90 per share1.20
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$177.65M0.78$1.06 per share13.71$15.44 per share0.94
LENSAR, Inc. stock logo
LNSR
LENSAR
$53.49M2.75N/AN/A$0.42 per share29.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
electroCore, Inc. stock logo
ECOR
electroCore
-$11.89M-$1.62N/AN/AN/A-47.84%-221.93%-69.17%11/12/2025 (Estimated)
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$107.25M-$2.61N/AN/AN/AN/A-163.32%-96.41%11/13/2025 (Estimated)
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
-$18.08M-$2.74N/A8.73N/A-11.22%-3.07%-2.01%12/4/2025 (Estimated)
LENSAR, Inc. stock logo
LNSR
LENSAR
-$31.40M-$4.21N/AN/A-84.49%-737.30%-72.60%11/6/2025 (Estimated)

Latest ECOR, INO, LNSR, and LAKE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/9/2025Q2 2026
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
-$0.04$0.36+$0.40$0.08$54.59 million$52.50 million
8/12/2025Q2 2025
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
-$0.63-$0.61+$0.02-$0.61$0.01 millionN/A
8/7/2025Q2 2025
LENSAR, Inc. stock logo
LNSR
LENSAR
-$0.0750-$0.15-$0.0750-$0.15$16.55 million$11.36 million
8/6/2025Q2 2025
electroCore, Inc. stock logo
ECOR
electroCore
-$0.32-$0.35-$0.03-$0.44$7.24 million$7.38 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
electroCore, Inc. stock logo
ECOR
electroCore
N/AN/AN/AN/AN/A
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/AN/AN/AN/AN/A
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
$0.120.83%N/AN/A 1 Years
LENSAR, Inc. stock logo
LNSR
LENSAR
N/AN/AN/AN/AN/A

Latest ECOR, INO, LNSR, and LAKE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/1/2025
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
quarterly$0.030.9%8/15/20258/15/20258/22/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
electroCore, Inc. stock logo
ECOR
electroCore
N/A
1.10
0.95
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
N/A
1.66
1.66
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
0.19
3.66
1.41
LENSAR, Inc. stock logo
LNSR
LENSAR
N/A
1.52
0.88

Institutional Ownership

CompanyInstitutional Ownership
electroCore, Inc. stock logo
ECOR
electroCore
26.74%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
26.79%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
71.69%
LENSAR, Inc. stock logo
LNSR
LENSAR
40.15%

Insider Ownership

CompanyInsider Ownership
electroCore, Inc. stock logo
ECOR
electroCore
13.80%
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
2.30%
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
1.91%
LENSAR, Inc. stock logo
LNSR
LENSAR
66.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
electroCore, Inc. stock logo
ECOR
electroCore
507.58 million6.54 millionNot Optionable
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
32053.14 million51.92 millionOptionable
Lakeland Industries, Inc. stock logo
LAKE
Lakeland Industries
2,1009.57 million9.39 millionOptionable
LENSAR, Inc. stock logo
LNSR
LENSAR
11011.94 million4.06 millionOptionable

Recent News About These Companies

Lensar (LNSR) Q2 Revenue Rises 10%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
electroCore stock logo

electroCore NASDAQ:ECOR

$4.80 +0.06 (+1.16%)
As of 02:54 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Inovio Pharmaceuticals stock logo

Inovio Pharmaceuticals NASDAQ:INO

$2.28 -0.11 (-4.41%)
As of 03:02 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Lakeland Industries stock logo

Lakeland Industries NASDAQ:LAKE

$14.50 -0.14 (-0.92%)
As of 03:01 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Lakeland Industries, Inc. manufactures and sells industrial protective clothing and accessories for the industrial and public protective clothing market worldwide. It offers firefighting and heat protective apparel to protect against fire; high-end chemical protective suits to provide protection from highly concentrated, toxic and/or lethal chemicals, and biological toxins; and limited use/disposable protective clothing, such as coveralls, laboratory coats, shirts, pants, hoods, aprons, sleeves, arm guards, caps, and smocks. The company provides durable woven garments, including electrostatic dissipative apparel used in electronics clean rooms; flame resistant meta aramid, para aramid, and FR cotton coveralls/pants/jackets used in petrochemical, refining operations, and electrical utilities; FR fabrics; and cotton and polycotton coveralls, lab coats, pants, and shirts. In addition, it provides high visibility clothing comprising reflective apparel, including vests, T-shirts, sweatshirts, jackets, coats, raingear, jumpsuits, hats, and gloves; and gloves and sleeves that are used in the automotive, glass, and metal fabrication industries. The company sells its products to a network of safety and industrial supply distributors through in-house sales teams, customer service group, and independent sales representatives. It serves end users, such as integrated oil, chemical/petrochemical, automobile, steel, glass, construction, smelting, cleanroom, janitorial, pharmaceutical, and high technology electronics manufacturers, as well as scientific, medical laboratories, and the utilities industry; and federal, state, and local governmental agencies and departments. Lakeland Industries, Inc. was incorporated in 1982 and is headquartered in Huntsville, Alabama.

LENSAR stock logo

LENSAR NASDAQ:LNSR

$12.32 -0.16 (-1.24%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.